Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePRNewsWire • 12/17/24
Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual MeetingPRNewsWire • 12/06/24
Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)PRNewsWire • 12/05/24
Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024PRNewsWire • 12/04/24
Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual MeetingPRNewsWire • 12/03/24
Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a BetZacks Investment Research • 11/29/24
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)PRNewsWire • 11/21/24
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High?Zacks Investment Research • 11/13/24
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/07/24
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/07/24
Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key MetricsZacks Investment Research • 11/04/24